MiNK Therapeutics, Inc. (INKT) Stock

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

MiNK Therapeutics, Inc. is led by CEO Jennifer S. Buell, employs 23 people, headquartered in US, publicly traded since 2021.

MiNK Therapeutics, Inc. (INKT) stock trades at $10.71 with a market capitalization of $54.65M. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.33, reflecting a net loss over the last twelve months, a negative price-to-book of -3.71, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $8.48 and $16.93, and currently trades 36.7% below its 52-week high.

On profitability, MiNK Therapeutics, Inc. generates a return on equity (ROE) of 83.45% (not meaningful, as shareholders' equity is negative), return on capital employed of -604.20%.

Official website: minktherapeutics.com

MiNK Therapeutics, Inc. by the numbers, 2019–2025

Between 2019 and 2025 MiNK Therapeutics, Inc. reported revenue of $1.0M rising to $0, a change of -100.0% across 7 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit rose to $-12.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-12.0M.

Borrowings fell from $27.0M to $5.0M, cash from operations was $-6.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged 33.5% over five years, and was 85.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

MiNK Therapeutics, Inc. (INKT) — frequently asked questions